VAXXINITY INC-A (VAXX) Forecast, Price Target & Analyst Ratings
NASDAQ:VAXX • US92244V1044
0.1111 USD
-0.02 (-15.26%)
At close: May 8, 2024
0.1107 USD
0 (-0.36%)
After Hours: 5/8/2024, 8:24:57 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VAXXINITY INC-A (VAXX).
Forecast Snapshot
Consensus Price Target
$15.30
+ 13,671.38% Upside
Next Earnings Forecast
Release DateAug 7, 2024
PeriodQ1 / 2024
EPS Estimate-$0.10
Revenue Estimate
ChartMill Buy Consensus
87.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$15.30
Upside
+ 13,671.38%
From current price of $0.11 to mean target of $15.30, Based on 8 analyst forecasts
Low
$15.15
Median
$15.30
High
$15.75
Price Target Revisions
1 Month
0.00%
3 Months
36.36%
Price Target Summary
8 analysts have analysed VAXX and the average price target is 15.3 USD. This implies a price increase of 13671.38% is expected in the next year compared to the current price of 0.1111.
The average price target has been revised upward by 36.36% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.50%
VAXX was analyzed by 8 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about VAXX.
In the previous month the buy percentage consensus was at a similar level.
VAXX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-09-08 | Baird | Initiate | Outperform |
| 2022-04-27 | Evercore ISI Group | Initiate | In-Line |
| 2021-12-07 | Jefferies | Initiate | Buy |
| 2021-12-06 | B of A Securities | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateAug 7, 2024
PeriodQ1 / 2024
EPS Estimate-$0.10
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q32.00%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
VAXX is expected to report earnings on 8/7/2024. The consensus EPS estimate for the next earnings is -0.1 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 560K | 70K -87.50% | -100.00% | 31.671M | 40.698M 28.50% | 74.763M 83.70% | 145.97M 95.24% | 234.72M 60.80% | |||||
| EBITDA YoY % growth | -13.55M | -31.56M -132.92% | -123.98M -292.84% | -76.612M 40.07% | -95.217M 24.56% | -108.946M -94.37% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.66M | -32.28M -136.31% | -125.08M -287.48% | -77.459M 39.25% | -61.191M 23.29% | -52.962M 9.13% | -60.907M -15.00% | -59.451M 2.39% | -49.555M 16.65% | -27.418M 44.67% | 37.391M 236.37% | 120.22M 221.52% | |
| Operating Margin | N/A | -5,764.29% | -178,685.71% | N/A | N/A | N/A | N/A | -187.71% | -121.76% | -36.67% | 25.62% | 51.22% | |
| EPS YoY % growth | N/A | N/A | N/A | -0.61 62.05% | -0.47 21.80% | -0.39 17.39% | -0.40 -2.63% | -0.42 -5.13% | -0.42 | -0.39 7.32% | -0.33 15.79% | -0.27 18.75% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.10 32.00% | -0.10 7.27% | -0.10 -2.00% | -0.08 20.00% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -13.441M 28.55% | -13.307M 7.78% | -13.173M 2.06% | -13.042M -11.95% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
3.50%
EPS Next 5 Year
3.26%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
VAXXINITY INC-A / VAXX Forecast FAQ
What do analysts expect the price target to be for VAXXINITY INC-A (VAXX)?
8 analysts have analysed VAXX and the average price target is 15.3 USD. This implies a price increase of 13671.38% is expected in the next year compared to the current price of 0.1111.
When does VAXXINITY INC-A (VAXX) report earnings?
VAXXINITY INC-A (VAXX) will report earnings on 2024-08-07, after the market close.
What are the consensus estimates for VAXXINITY INC-A (VAXX) next earnings?
The consensus EPS estimate for the next earnings of VAXXINITY INC-A (VAXX) is -0.1 USD and the consensus revenue estimate is 0 USD.